Influenza Like Symptoms — Patent Landscape
3
Approved drugs
20
Active US patents
64/100
Avg vulnerability
—
Annual revenue covered
Originators in Influenza Like Symptoms
Cliff calendar — next 15 years
1
27
8
29
2
30
6
32
3
35
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Advil
ibuprofen
|
Generic (originally Boots Group) | 14 | 70 | — | 2029-09-30 |
|
Tussionex Pennkinetic
CHLORPHENIRAMINE MALEATE
|
Bayer | 3 | 60 | — | 2027-02-28 |
|
Mucinex
guaifenesin
|
Generic (multiple manufacturers) | 3 | 62 | — | 2035-11-13 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 11806400 | Advil | method of use | 76 | 2032-03-16 |
| 11806400 | Advil | method of use | 76 | 2032-03-16 |
| 8735452 | Advil | method of use | 73 | 2029-09-30 |
| 8871810 | Advil | method of use | 73 | 2029-09-30 |
| 9295639 | Advil | method of use | 68 | 2029-09-30 |
| 9649284 | Advil | method of use | 68 | 2029-09-30 |
| 9138404 | Advil | method of use | 68 | 2029-09-30 |
| 8871810 | Advil | method of use | 68 | 2029-09-30 |
| 8735452 | Advil | method of use | 68 | 2029-09-30 |
| 9114068 | Advil | method of use | 68 | 2029-09-30 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 9107921 | Tussionex Pennkinetic | formulation | 48 | 2032-01-03 |
| 9808431 | Mucinex | method of use | 62 | 2035-11-13 |
| 10105324 | Mucinex | method of use | 62 | 2035-11-13 |
| 9549907 | Mucinex | method of use | 62 | 2035-11-13 |
| 7863287 | Tussionex Pennkinetic | formulation | 65 | 2027-02-28 |
| 9072710 | Advil | method of use | 68 | 2032-03-16 |
| 9072661 | Advil | method of use | 68 | 2032-03-16 |
| 9066942 | Tussionex Pennkinetic | method of use | 68 | 2032-01-03 |
| 9012508 | Advil | method of use | 68 | 2030-09-14 |
| 9012508 | Advil | method of use | 68 | 2030-09-14 |
Related
- Influenza Like Symptoms — full disease profile
- AI Patent Landscape Report — type "influenza like symptoms" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner